サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1629900

使い捨て自動注射器の世界市場 - 2025年～2033年

Global Disposable Autoinjectors Market - 2025-2033

出版日
ページ情報
英文 159 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
使い捨て自動注射器の世界市場 - 2025年～2033年
出版日: 2024年12月30日
発行: DataM Intelligence
ページ情報: 英文 159 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

世界の使い捨て自動注射器市場は、2024年に7億1,230万米ドルに達し、2033年には30億7,320万米ドルに達すると予測され、予測期間2025-2033年のCAGRは17.8%で成長します。

使い捨て自動注射器は、皮下または筋肉内への薬剤の自己投与用に設計された医療機器であり、一般的にはあらかじめ充填された注射器の形をしています。これらの器具は、薬剤が注入された後に廃棄されることを意味する一回使用の性質が特徴です。使用者は自動注射器を皮膚に当て、押すだけで作動させることができます。注射針は使用後すぐに収納されるため、安全性が確保され、針刺しによる怪我を防ぐことができます。

使い捨て自動注射器の世界市場の需要は大きく伸びています。例えば、米国国立衛生研究所（NIH）によると、20社以上の製薬会社が約80種類の自己注射器を開発しています。また、50種類近くの薬剤が、自己注射器による投与のための配合剤として開発されています。このうち62％が使い捨てタイプです。使い捨て自動注射器の市場需要は、慢性疾患の蔓延、薬剤製剤の進歩、自己投与への移行など、いくつかの重要な要因により着実に増加しています。

市場力学：

促進要因と抑制要因

慢性疾患の有病率の上昇

慢性疾患の有病率の上昇は、使い捨て自動注射器市場の成長を大きく後押ししており、予測期間中も市場を牽引するとみられます。糖尿病の世界の増加に伴い、自動注射器のようなインスリン送達システムの需要が増加しています。例えば、世界保健機関（WHO）によると、世界では約8億3,000万人が糖尿病を患っており、その大半は低・中所得国に住んでいます。糖尿病患者数の増加は、インスリン投与用自己注射器に対する需要を促進しています。自己注射器は、患者が自宅でインスリンを投与するための便利で安全な方法を提供するためであり、これは糖尿病の状態を管理するために極めて重要です。

自己免疫疾患やがんの治療に生物製剤やモノクローナル抗体の使用が増加していることが、自動注射器の需要を加速しています。これらの薬剤は正確な投与と確実な投与を必要とするが、自動注射器はそれを可能にします。関節リウマチやその他の自己免疫疾患用のヒュミラペンのようなデバイスのイントロダクションは、生物製剤に対する市場の反応を例証しており、患者に優しい自己投与デバイスに対する需要の増加を示しています。

糖尿病、関節リウマチ、多発性硬化症などの様々な慢性疾患の有病率の増加は、その利便性と目立たないように状態を管理する能力により、自己投与への顕著なシフトです。使い捨て自動注射器は、医療従事者の介入を必要とせずに患者が自宅で薬を管理できるようにすることで、この動向に対応しています。

例えば、大正製薬株式会社は2024年1月、TNFa阻害剤「ナノゾラ30mg S.C.注射用使い捨て自動注射器」（一般名：オゾラリズマブ、（遺伝子組換え））を発売すると発表しました。本剤は、関節リウマチ患者さんの使いやすさに配慮したデバイスを採用しています。大正製薬は、「ナノゾーラ30mgシリンジS.C.注射用」と「ナノゾーラ30mgオートインジェクターS.C.注射用」を提供することで、関節リウマチ患者に新たな治療選択肢を提供することを目指します。

代替ドラッグデリバリーシステムの利用可能性

代替ドラッグデリバリーシステムの利用可能性は、使い捨て自動注射器市場の成長を妨げると予想されます。これらの代替システムは、従来の注射器、吸入器、その他のドラッグデリバリー形態を含み、費用対効果、使いやすさ、さまざまな治療経験といった競合優位性を提供することができます。

従来の注射器は、特に低資源環境において、ドラッグデリバリーの費用対効果に優れた選択肢であり続けています。それらは広く入手可能であり、ヘルスケア提供者にも患者にもなじみがあるため、使い捨て自動注射器に代わる魅力的な選択肢となっています。例えば、地域によっては、使い捨て自動注射器を使用するコストが従来の注射器と比較して著しく高く、それが採用の妨げになることもあります。予算が限られているヘルスケアシステムでは、従来の注射器が好まれるため、自動注射器の普及が遅れる可能性があります。

Auvi-Qのような、ブランド化されたエピネフリン自己注射器の後発品や低価格の代替品が人気を集めています。これらの代替品は、同様の効能を持ちながらも低価格で提供されるため、より多くの患者が利用しやすくなっています。この競合は、コスト意識の高い消費者がより手頃な選択肢を選ぶため、ブランド品の市場シェアを低下させる可能性があります。

ホルモン補充療法や慢性疼痛管理のような症状に対する経皮パッチは、注射を完全に避ける代替手段を提供します。これらのパッチは、注射針や自動注射器の必要性を回避し、長期間にわたって皮膚から薬剤を供給します。このようなパッチが受け入れられるようになれば、使い捨ての自動注射器の需要を減らすことができます。例えば、パーキンソン病治療用のNeuproパッチは、一部の患者にとって自動注射器に代わる有効な治療法となります。

目次

第1章 市場イントロダクションと範囲

  • 報告書の目的
  • 調査範囲と定義
  • 調査範囲

第2章 エグゼクティブの洞察と重要なポイント

  • 市場のハイライトと戦略的ポイント
  • 主な動向と将来の予測
  • タイプ別
  • 用途別
  • エンドユーザー別
  • 地域別

第3章 市場力学

  • 影響要因
    • 促進要因
      • 慢性疾患の蔓延
      • 技術の進歩の高まり
    • 抑制要因
      • 代替ドラッグデリバリーシステムの利用可能性
    • 機会
    • 影響分析

第4章 戦略的洞察と業界展望

  • 市場のリーダーと先駆者
    • 新たな先駆者と著名な企業
    • 最大の売上を誇るブランドを確立したリーダー
    • 確立された製品を持つ市場リーダー
  • 新興スタートアップ企業と主要イノベーター
  • CXOの視点
  • 最新の開発とブレークスルー
  • ケーススタディ/進行中の調査
  • 規制と償還の情勢
    • 北米
    • 欧州
    • アジア太平洋地域
    • ラテンアメリカ
    • 中東・アフリカ
  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 特許分析
  • SWOT分析
  • アンメットニーズとギャップ
  • 市場参入と拡大のための推奨戦略
  • シナリオ分析ベストケース、ベースケース、ワーストケースの予測
  • 価格分析と価格市場力学

第5章 使い捨て自動注射器市場、タイプ別

  • プレフィルドオートインジェクター
  • 充填可能な自動注射器

第6章 使い捨て自動注射器市場、用途別

  • 糖尿病
  • 関節リウマチ
  • 多発性硬化症
  • アナフィラキシー
  • その他

第7章 使い捨て自動注射器市場、エンドユーザー別

  • 病院
  • 専門クリニック
  • ホームケア設定
  • その他

第8章 使い捨て自動注射器市場、地域別、市場分析と成長機会

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • スペイン
    • イタリア
    • その他欧州地域
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
    • 韓国
    • その他アジア太平洋地域
  • 中東・アフリカ

第9章 競合情勢と市場ポジショニング

  • 競合状況の概要と主要な市場企業
  • 市場シェア分析とポジショニングマトリックス
  • 戦略的パートナーシップ、合併、買収
  • 製品ポートフォリオとイノベーションにおける主な発展
  • 企業ベンチマーク

第10章 企業プロファイル

  • Becton, Dickinson, and Company
    • 会社概要
    • 製品ポートフォリオと概要
    • 財務概要
    • 主な発展
    • SWOT分析
  • Ypsomed AG
  • Owen Mumford Inc.
  • Phillips Medisize
  • SHL Medical
  • Stevanato Group
  • Faxne
  • Dali Medical Devices

第11章 仮定と調査手法

  • データ収集方法
  • データの三角測量
  • 予測技術
  • データの検証と検証

第12章 付録

目次
Product Code: MD8934

The global disposable autoinjectors market reached US$ 712.3 million in 2024 and is expected to reach US$ 3,073.2 million by 2033, growing at a CAGR of 17.8% during the forecast period 2025-2033.

A disposable autoinjector is a medical device designed for the subcutaneous or intramuscular self-administration of medication, which is typically in the form of a pre-filled syringe. These devices are characterized by their single-use nature, meaning they are disposed of after the medication has been injected. The user simply positions the autoinjector against the skin and activates it with a simple push. The device then automatically delivers the medication via a needle hidden within the device, which retracts immediately after use to ensure safety and prevent needle-stick injuries.

The demand for disposable autoinjectors market is experiencing significant growth. For instance, according to the National Institute of Health (NIH), more than 20 pharmaceutical companies have developed nearly about 80 autoinjectors. Nearly 50 drugs are developed as combination products for administration using autoinjectors. Among these, 62% of the autoinjectors are disposable. The market demand for disposable autoinjectors has been steadily increasing due to several key factors including the growing prevalence of chronic diseases, advancements in drug formulations and the push towards self-administration.

Market Dynamics: Drivers & Restraints

Rising prevalence of chronic diseases

The rising prevalence of chronic diseases is significantly driving the growth of the disposable autoinjectors market and is expected to drive the market over the forecast period. With the global rise in diabetes, the demand for insulin delivery systems like autoinjectors has increased. For instance, according to the World Health Organization (WHO), about 830 million people worldwide have diabetes, the majority living in low-and middle-income countries. The rising number of diabetes patients is driving demand for autoinjectors for insulin administration as autoinjectors offer a convenient and safer method for patients to administer insulin at home, which is crucial for managing the condition.

The growing use of biologics and monoclonal antibodies for treating autoimmune diseases and cancer has spurred demand for autoinjectors. These drugs require precise dosing and reliable administration, which autoinjectors provide. The introduction of devices like the Humira Pen for rheumatoid arthritis and other autoimmune diseases exemplifies the market's response to biologics, showing an increased demand for patient-friendly, self-administration devices.

The increasing prevalence of various chronic diseases such as diabetes, rheumatoid arthritis, multiple sclerosis and others is a notable shift towards self-administration due to its convenience and the ability to manage conditions discreetly. Disposable autoinjectors cater to this trend by allowing patients to administer their medications at home without the need for healthcare provider intervention.

For instance, in January 2024, Taisho Pharmaceutical Co., Ltd. announced that the Nanozora 30 mg Disposable Autoinjector for S.C. Injection (generic name: ozoralizumab, (recombinant)), a TNFa inhibitor is launched. The drug employs a device that considers ease of use for patients with rheumatoid arthritis (RA). Taisho aims to provide new treatment options for patients with RA, offering Nanozora 30mg Syringes for S.C. Injection and Nanozora 30mg Autoinjector for S.C. Injection.

Availability of alternative drug delivery systems

The availability of alternative drug delivery systems is expected to hamper the growth of the disposable autoinjectors market. These alternatives, which include traditional syringe injections, inhalers and other forms of drug delivery, can offer competitive advantages such as cost-effectiveness, ease of use and different treatment experiences.

Traditional syringes remain a cost-effective option for drug delivery, especially in low-resource settings. They are widely available and familiar to both healthcare providers and patients, making them an attractive alternative to disposable autoinjectors. For instance, in some regions, the cost of using disposable autoinjectors can be significantly higher compared to conventional syringes, which can deter adoption. In healthcare systems where budgets are limited, the preference for traditional syringes can slow the uptake of autoinjectors.

Generic and low-cost alternatives to branded epinephrine autoinjectors, like Auvi-Q, have gained traction. These alternatives offer similar efficacy at a lower price point, making them more accessible to a broader patient population. This competition can reduce the market share of branded disposable autoinjectors, as cost-conscious consumers opt for more affordable options.

Transdermal patches for conditions like hormone replacement therapy and chronic pain management offer an alternative that avoids injections altogether. These patches deliver medication through the skin over an extended period, bypassing the need for needles and auto-injectors. The growing acceptance of such patches can reduce the demand for disposable auto-injectors. For example, the Neupro patch for Parkinson's disease provides a viable alternative to auto-injector treatments for some patients.

Segment Analysis

The global disposable autoinjectors market is segmented based on type, application, end-user and region.

Product Type:

The prefilled autoinjectors segment is expected to dominate the disposable autoinjectors market share

Prefilled autoinjectors are designed for ease of use, allowing patients to self-administer medications without the need for healthcare provider assistance. These devices typically come pre-filled with the medication, eliminating the need for patients to fill the device themselves. The design of prefilled autoinjectors, such as those used for insulin delivery and other medications, simplifies the administration process and reduces the potential for user error.

For instance, in January 2024, Taisho Pharmaceutical Co., Ltd. launched the Nanozora 30 mg Autoinjector for S.C. Injection (generic name: ozoralizumab, (recombinant)), a TNFa inhibitor. Nanozora 30mg Autoinjector for S.C. Injection is a single-use autoinjector dosage form, prefilled with the same drug as the syringe dosage form Nanozora 30mg Syringe for S.C. Injection. Users can easily inject the drug simply by pressing the injector against the skin. The needle covering will be locked after injection to prevent needle-piercing accidents.

Many prefilled autoinjectors come equipped with smart features such as Bluetooth connectivity for monitoring injection history and dosage reminders. These features enhance patient management and engagement by providing real-time data to patients and healthcare providers. These smart devices also allows patients to monitor their medication usage and receive reminders, making it a preferred choice over traditional devices.

For instance, in May 2022, Stevanato Group S.p.A., a global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, signed an exclusive agreement with leading medical device developer and manufacturer Owen Mumford Ltd. for its Aidaptus auto-injector. Aidaptus is a 2-step, single-use auto-injector with a versatile design that accommodates both 1mL and 2.25 mL prefilled glass syringes in the same base device.

Geographical Analysis

North America is expected to hold a significant position in the disposable autoinjectors market share

North America, particularly the United States, boasts a highly developed healthcare infrastructure, which includes advanced hospitals, research facilities, and specialized clinics. This infrastructure supports the adoption of advanced drug delivery technologies such as disposable auto-injectors. For instance, major healthcare providers and facilities across the U.S. utilize auto-injectors for treating conditions like rheumatoid arthritis and multiple sclerosis, which are common in the region. This widespread usage creates a strong demand for disposable autoinjectors.

For instance, in May 2021, Phillips-Medisize, a Molex company, unveiled the Aria Smart Autoinjector platform to unlock innovation, differentiation and sustainability in the digital drug delivery device market. This latest advancement introduces a small smart injection device featuring single-use disposable cassettes to elevate patient care while reducing environmental impact.

In the U.S., self-administration of medications using auto-injectors has been widely adopted for chronic disease management. For example, therapies for rheumatoid arthritis and multiple sclerosis are commonly delivered via auto-injectors like the Sensoready and Rebif, respectively. The convenience and safety of these devices make them highly preferred among patients, contributing to the dominance of North America in this market.

Asia-Pacific is growing at the fastest pace in the disposable autoinjectors market

Countries in the APAC region, particularly China and India, are witnessing substantial increases in healthcare spending as governments allocate more resources towards improving healthcare infrastructure. For instance, China's National Healthcare Security Administration has been expanding insurance coverage to include more advanced medical devices like auto-injectors. This expansion boosts the adoption of these devices across the region.

There is growing awareness among patients in the APAC region regarding the benefits of self-administered therapies. This awareness is being driven by healthcare campaigns, education programs, and the increased availability of auto-injectors through pharmacies and healthcare facilities. For instance, countries like India are seeing increased awareness about the benefits of using prefilled auto-injectors for treating conditions like rheumatoid arthritis.

The younger generation in the APAC region is more inclined towards modern technologies, including those related to healthcare. This demographic trend supports the adoption of auto-injectors over traditional methods. The increasing urbanization and better education levels are also factors contributing to higher acceptance rates of self-administered injectables.

Competitive Landscape

The major global players in the disposable autoinjectors market include Becton, Dickinson, and Company, Ypsomed AG, Owen Mumford Inc., Phillips Medisize, SHL Medical, Stevanato Group, Faxne, Dali Medical Devices and among others.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global disposable autoinjectors market report delivers a detailed analysis with 56 key tables, more than 52 visually impactful figures, and 159 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

  • 1.1. Objectives of the Report
  • 1.2. Report Coverage & Definitions
  • 1.3. Report Scope

2. Executive Insights and Key Takeaways

  • 2.1. Market Highlights and Strategic Takeaways
  • 2.2. Key Trends and Future Projections
  • 2.3. Snippet by Type
  • 2.4. Snippet by Application
  • 2.5. Snippet by End-User
  • 2.6. Snippet by Region

3. Dynamics

  • 3.1. Impacting Factors
    • 3.1.1. Drivers
      • 3.1.1.1. Rising Prevalence of Chronic Diseases
      • 3.1.1.2. Rising Technological Advancements
    • 3.1.2. Restraints
      • 3.1.2.1. Availability of Alternative Drug Delivery Systems
    • 3.1.3. Opportunity
    • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

  • 4.1. Market Leaders and Pioneers
    • 4.1.1. Emerging Pioneers and Prominent Players
    • 4.1.2. Established leaders with largest selling Brand
    • 4.1.3. Market leaders with established Product
  • 4.2. Emerging Startups and Key Innovators
  • 4.3. CXO Perspectives
  • 4.4. Latest Developments and Breakthroughs
  • 4.5. Case Studies/Ongoing Research
  • 4.6. Regulatory and Reimbursement Landscape
    • 4.6.1. North America
    • 4.6.2. Europe
    • 4.6.3. Asia Pacific
    • 4.6.4. Latin America
    • 4.6.5. Middle East & Africa
  • 4.7. Porter's Five Force Analysis
  • 4.8. Supply Chain Analysis
  • 4.9. Patent Analysis
  • 4.10. SWOT Analysis
  • 4.11. Unmet Needs and Gaps
  • 4.12. Recommended Strategies for Market Entry and Expansion
  • 4.13. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 4.14. Pricing Analysis and Price Dynamics

5. Disposable Autoinjectors Market, By Type

  • 5.1. Introduction
    • 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 5.1.2. Market Attractiveness Index, By Type
  • 5.2. Prefilled Autoinjectors*
    • 5.2.1. Introduction
    • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 5.3. Fillable Autoinjectors

6. Disposable Autoinjectors Market, By Application

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 6.1.2. Market Attractiveness Index, By Application
  • 6.2. Diabetes*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Rheumatoid Arthritis
  • 6.4. Multiple Sclerosis
  • 6.5. Anaphylaxis
  • 6.6. Others

7. Disposable Autoinjectors Market, By End-User

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 7.1.2. Market Attractiveness Index, By End-User
  • 7.2. Hospitals*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Specialty Clinics
  • 7.4. Homecare Settings
  • 7.5. Others

8. Disposable Autoinjectors Market, By Regional Market Analysis and Growth Opportunities

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 8.1.2. Market Attractiveness Index, By Region
  • 8.2. North America
    • 8.2.1. Introduction
    • 8.2.2. Key Region-Specific Dynamics
    • 8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.2.6.1. U.S.
      • 8.2.6.2. Canada
      • 8.2.6.3. Mexico
  • 8.3. Europe
    • 8.3.1. Introduction
    • 8.3.2. Key Region-Specific Dynamics
    • 8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.3.6.1. Germany
      • 8.3.6.2. U.K.
      • 8.3.6.3. France
      • 8.3.6.4. Spain
      • 8.3.6.5. Italy
      • 8.3.6.6. Rest of Europe
  • 8.4. South America
    • 8.4.1. Introduction
    • 8.4.2. Key Region-Specific Dynamics
    • 8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.4.6.1. Brazil
      • 8.4.6.2. Argentina
      • 8.4.6.3. Rest of South America
  • 8.5. Asia-Pacific
    • 8.5.1. Introduction
    • 8.5.2. Key Region-Specific Dynamics
    • 8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.5.6.1. China
      • 8.5.6.2. India
      • 8.5.6.3. Japan
      • 8.5.6.4. South Korea
      • 8.5.6.5. Rest of Asia-Pacific
  • 8.6. Middle East and Africa
    • 8.6.1. Introduction
    • 8.6.2. Key Region-Specific Dynamics
    • 8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

9. Competitive Landscape and Market Positioning

  • 9.1. Competitive Overview and Key Market Players
  • 9.2. Market Share Analysis and Positioning Matrix
  • 9.3. Strategic Partnerships, Mergers & Acquisitions
  • 9.4. Key Developments in Product Portfolios and Innovations
  • 9.5. Company Benchmarking

10. Company Profiles

  • 10.1. Becton, Dickinson, and Company*
    • 10.1.1. Company Overview
    • 10.1.2. Product Portfolio and Description
    • 10.1.3. Financial Overview
    • 10.1.4. Key Developments
    • 10.1.5. SWOT Analysis
  • 10.2. Ypsomed AG
  • 10.3. Owen Mumford Inc.
  • 10.4. Phillips Medisize
  • 10.5. SHL Medical
  • 10.6. Stevanato Group
  • 10.7. Faxne
  • 10.8. Dali Medical Devices

LIST NOT EXHAUSTIVE

11. Assumption and Research Methodology

  • 11.1. Data Collection Methods
  • 11.2. Data Triangulation
  • 11.3. Forecasting Techniques
  • 11.4. Data Verification and Validation

12. Appendix

  • 12.1. About Us and Services
  • 12.2. Contact Us